In vitro antifungal susceptibility pattern of Candida species isolated from gastroesophageal candidiasis
Gastroenterology and Hepatology from Bed to Bench,
26 April 2021
Aim: The current study aimed to determine the antifungal susceptibility profile of Candida species isolated from gastroesophageal lesions
Background: Gastroesophageal candidiasis is a common infection among HIV/AIDS patients and those who are taking PPI and H2RAs drugs. More than 20 Candida spp. can cause different types of mucocutaneous infections in humans. The present study was conducted to assess the antifungal susceptibility testing of clinical Candida spp. isolated from gastroesophageal lesions.
Methods: Forty-eight clinical samples were collected from 60 patients undergoing endoscopy. All isolates were identified by molecular techniques (PCR-RFLP). The profiles of the susceptibility of Candida spp. to seven antifungal agents, i.e. amphotericin B, fluconazole, itraconazole, luliconazole, voriconazole, posaconazole, and caspofungin, were evaluated using broth microdilution.
Results: The susceptibility profile of Candida isolates revealed 100% sensitivity to amphotericin B, caspofungin, and voriconazole. Moreover, fluconazole- (6.5%) and itraconazole-resistant (2.1%) isolates were observed.
Conclusion: With regard to the increase in fluconazole-resistant Candida species, it is necessary to determine the in vitro antifungal susceptibility pattern of clinical isolates for the best management of infection and to prevent the emergence of drug resistant isolates.
Keywords: antifungal susceptibility testing, Candida spp., gastroesophageal.
(Please cite as: Mirshekar M, Emami MH, Mohammadi R. In vitro antifungal susceptibility pattern of Candida species isolated from gastroesophageal candidiasis. Gastroenterol Hepatol Bed Bench 2021;14(3):260-266).
- Antifungal susceptibility testing
- Candida spp.
Samaranayake L, Fidel P, Sweet S, Teanpaisan R, Coogan M, Blignaut E, et al. Fungal infections associated with HIV infection. Oral Dis 2002;8:151-60.
Choi JH, Lee CG, Lim YJ, Kang HW, Lim CY, Choi J-S. Prevalence and risk factors of esophageal candidiasis in healthy individuals: a single center experience in Korea. Yonsei Med 2013;54:160-5.
Wilheim AB, Miranda-Filho DdB, Nogueira RA, Rêgo RSdM, Lima KdM, Pereira LMMB. The resistance to fluconazole in patients with esophageal candidiasis. Arquivos de gastroenterologia 2009;46:32-7.
Kliemann DA, Pasqualotto AC, Falavigna M, Giaretta T, Severo LC. Candida esophagitis: species distribution and risk factors for infection. Rev Inst Med Trop 2008;50:261-3.
Sanglard D. Emerging threats in antifungal-resistant fungal pathogens. Front Med 2016;3:11.
Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. BioMed Res Int 2013; 2013: 204237.
Moges B, Bitew A, Shewaamare A. Spectrum and the in vitro antifungal susceptibility pattern of yeast isolates in Ethiopian HIV patients with oropharyngeal candidiasis. Int J Microbiol 2016;2016:3037817.
Mottaghi B, Emami MH, Riahi P, Fahim A, Rahimi H, Mohammadi R. Candida colonization of the esophagus and gastric mucosa; a comparison between patients taking proton pump inhibitors and those taking histamine receptor antagonist drugs. Gastroenterol Hepatol Bed Bench. In Press.
CLSI. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement M27-S4. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2012.
Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts. CLSI supplement M60. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
Pfaller M, Diekema D. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012;50:2846-56.
Mulu A, Kassu A, Anagaw B, Moges B, Gelaw A, Alemayehu M, et al. Frequent detection of ‘azole’resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC Infect Dis 2013;13:82.
Lake D, Kumweiler J, Beer M, Buell D, Islam M. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy 1996;42:308-14.
Prasad R, Kapoor K. Multidrug resistance in yeast Candida. International Rev Cytol 2005;242:215-48.
Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from US population-based surveillance. Antimicrob Agents Chemother 2010;54:5042-7.
Mohamed AA, Lu X-l, Mounmin FA. Diagnosis and treatment of esophageal candidiasis: Current updates. Can J Gastroenterol Hepatol 2019;2019.
Rosołowski M, Kierzkiewicz M. Etiology, diagnosis and treatment of infectious esophagitis. Przeglad gastroenterologiczny 2013;8:333-39.
Xiao M, Fan X, Chen SC-A, Wang H, Sun Z-Y, Liao K, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother 2015;70:802-10.
Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201–5.
Koga H, Nanjoh Y, Makimura K, Tsuboi R. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol 2009;47:640-7.
Uchida K, Nishiyama Y, Yamaguchi H. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother 2004;10:216-9.
Donghui TY, Seger DL, Peterson JF, Kumar RN, Bates DW. Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. BMC Infect Dis 2006;6:173-78.
Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematology Am Soc Hematol Educ Program 2013;2013:423-7.
Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta‐analysis of randomised‐controlled trials. Br J Haematol 2005;131:22-8.
Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Eng J Med 1991;325:1274-7.
Zhang L, Xiao M, Watts MR, Wang H, Fan X, Kong F, et al. Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy. BMC Infect Dis 2015;15:340.
Ngouana TK, Drakulovski P, Krasteva D, Toghueo RK, Kouanfack C, Reynes J, et al. Genetic diversity of the Hwp1 gene and HIS3, EF3, CDC3 microsatellites and antifungal susceptibility profiles of Candida albicans isolates from Yaounde HIV-infected patients. Med Mycol 2017;55:546-54.
Shokouhi T, Bandalizadeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of Candida species isolated from oropharyngeal lesions of patients with cancer to some antifungal agents. Jundishapur J Microbiol 2011;4:19-26.
Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med 2010;13:282-7.
Kumar P, Mohan S, Verma A, Baijal SS. Candida esophagitis in achalasia cardia: Case report and review of literature. Saudi J Gastroenterol 2007;13:88-90.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times